Effectiveness of blonanserin for patients with drug treatment-resistant schizophrenia and dopamine supersensitivity: A retrospective analysis

Asian Journal of Psychiatry

Volumn 24, Issue , 2016, Pages 28-32

  Tachibana, Masumi ^a,b   Niitsu, Tomihisa ^a   Watanabe, Motoki ^b   Hashimoto, Tasuku ^a   Kanahara, Nobuhisa ^c   Ishikawa, Masatomo ^a   Iyo, Masaomi ^a,c  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Fujita Works   (Japan)

^c CHIBA UNIVERSITY   (Japan)

Author keywords

Blonanserin; Dopamine supersensitivity psychosis; DSP; Treatment resistant schizophrenia; TRS

Indexed keywords

BLONANSERIN; CHLORPROMAZINE; DOPAMINE; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; PIPERIDINE DERIVATIVE;

ADD ON THERAPY; ADULT; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DOPAMINE SUPERSENSITIVITY PSYCHOSIS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GLOBAL ASSESSMENT OF FUNCTIONING; HUMAN; MALE; MIDDLE AGED; PRIORITY JOURNAL; PSYCHOSIS; RETROSPECTIVE STUDY; SCHIZOPHRENIA; SCORING SYSTEM; TREATMENT RESISTANT SCHIZOPHRENIA; DRUG RESISTANCE; OUTCOME ASSESSMENT; PSYCHOLOGICAL RATING SCALE;

ADULT; ANTIPSYCHOTIC AGENTS; BRIEF PSYCHIATRIC RATING SCALE; DOPAMINE; DRUG RESISTANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PIPERAZINES; PIPERIDINES; PSYCHIATRIC STATUS RATING SCALES; RETROSPECTIVE STUDIES; SCHIZOPHRENIA;

EID: 84983393046     PISSN: 18762018     EISSN: 18762026     Source Type: Journal    
DOI: 10.1016/j.ajp.2016.08.014     Document Type: Article

References (37)

1. Agid, O., Arenovich, T., Sajeev, G., Zipursky, R.B., Kapur, S., Foussias, G., Remington, G., An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis. J. Clin. Psychiatry 72 (2011), 1439–1444.
2. Austin, S.F., Mors, O., Budtz-Jorgensen, E., Secher, R.G., Hjorthoj, C.R., Bertelsen, M., Jeppesen, P., Petersen, L., Thorup, A., Nordentoft, M., Long-term trajectories of positive and negative symptoms in first episode psychosis: a 10 year follow-up study in the OPUS cohort. Schizophr. Res. 168 (2015), 84–91.
3. Bruijnzeel, D., Suryadevara, U., Tandon, R., Antipsychotic treatment of schizophrenia: an update. Asian J. Psychiatr. 11 (2014), 3–7.
4. Buchanan, R.W., Kreyenbuhl, J., Kelly, D.L., Noel, J.M., Boggs, D.L., Fischer, B.A., Himelhoch, S., Fang, B., Peterson, E., Aquino, P.R., Keller, W., Schizophrenia Patient Outcomes Research, T., The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr. Bull. 36 (2010), 71–93.
5. Chouinard, G., Chouinard, V.A., Atypical antipsychotics: CATIE study, drug-induced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes. Psychother. Psychosom. 77 (2008), 69–77.
6. Chouinard, G., Jones, B.D., Annable, L., Neuroleptic-induced supersensitivity psychosis. Am. J. Psychiatry 135 (1978), 1409–1410.
7. Chouinard, G., Annable, L., Ross-Chouinard, A., Mercier, P., A 5-year prospective longitudinal study of tardive dyskinesia: factors predicting appearance of new cases. J. Clin. Psychopharmacol. 8 (1988), 21S–26S.
8. Chouinard, G., Severe cases of neuroleptic-induced supersensitivity psychosis: diagnostic criteria for the disorder and its treatment. Schizophr. Res. 5 (1991), 21–33.
9. Fallon, P., Dursun, S.M., A naturalistic controlled study of relapsing schizophrenic patients with tardive dyskinesia and supersensitivity psychosis. J. Psychopharmacol. 25 (2011), 755–762.
10. Freedman, R., Schizophrenia. N. Engl. J. Med. 349 (2003), 1738–1749.
11. Huang, M., Panos, J.J., Kwon, S., Oyamada, Y., Rajagopal, L., Meltzer, H.Y., Comparative effect of lurasidone and blonanserin on cortical glutamate, dopamine, and acetylcholine efflux: role of relative serotonin (5-HT)2A and DA D2 antagonism and 5-HT1A partial agonism. J. Neurochem. 128 (2014), 938–949.
12. Huang, M., Kwon, S., Oyamada, Y., Rajagopal, L., Miyauchi, M., Meltzer, H.Y., Dopamine D3 receptor antagonism contributes to blonanserin-induced cortical dopamine and acetylcholine efflux and cognitive improvement. Pharmacol. Biochem. Behav. 138 (2015), 49–57.
13. Inoue, A., Miki, S., Seto, M., Kikuchi, T., Morita, S., Ueda, H., Misu, Y., Nakata, Y., Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum. Eur. J. Pharmacol. 321 (1997), 105–111.
14. Inoue, T., Osada, K., Tagawa, M., Ogawa, Y., Haga, T., Sogame, Y., Hashizume, T., Watanabe, T., Taguchi, A., Katsumata, T., Yabuki, M., Yamaguchi, N., Blonanserin, a novel atypical antipsychotic agent not actively transported as substrate by P-glycoprotein. Prog. Neuropsychopharmacol. Biol. Psychiatry 39 (2012), 156–162.
15. Iyo, M., Tadokoro, S., Kanahara, N., Hashimoto, T., Niitsu, T., Watanabe, H., Hashimoto, K., Optimal extent of dopamine D2 receptor occupancy by antipsychotics for treatment of dopamine supersensitivity psychosis and late-onset psychosis. J. Clin. Psychopharmacol. 33 (2013), 398–404.
16. Juarez-Reyes, M.G., Shumway, M., Battle, C., Bacchetti, P., Hansen, M.S., Hargreaves, W.A., Clozapine eligibility: the effect of stringent criteria on ethnic, gender and age subgroups of schizophrenic patients. Prog. Neuropsychopharmacol. Biol. Psychiatry. 20 (1996), 1341–1352.
17. Kane, J.M., Correll, C.U., The role of clozapine in treatment-Resistant schizophrenia. JAMA Psychiatry 73 (2016), 187–188.
18. Kane, J.M., Treatment strategies to prevent relapse and encourage remission. J. Clin. Psychiatry 68:Suppl 14 (2007), 27–30.
19. Kimura, H., Kanahara, N., Watanabe, H., Iyo, M., Potential treatment strategy of risperidone in long-acting injectable form for schizophrenia with dopamine supersensitivity psychosis. Schizophr. Res. 145 (2013), 130–131.
20. Kimura, H., Kanahara, N., Komatsu, N., Ishige, M., Muneoka, K., Yoshimura, M., Yamanaka, H., Suzuki, T., Komatsu, H., Sasaki, T., Hashimoto, T., Hasegawa, T., Shiina, A., Ishikawa, M., Sekine, Y., Shiraishi, T., Watanabe, H., Shimizu, E., Hashimoto, K., Iyo, M., A prospective comparative study of risperidone long-acting injectable for treatment-resistant schizophrenia with dopamine supersensitivity psychosis. Schizophr. Res. 155 (2014), 52–58.
21. Kirkpatrick, B., Alphs, L., Buchanan, R.W., The concept of supersensitivity psychosis. J. Nerv. Ment. Dis. 180 (1992), 265–270.
22. Lieberman, J., Jody, D., Geisler, S., Alvir, J., Loebel, A., Szymanski, S., Woerner, M., Borenstein, M., Time course and biologic correlates of treatment response in first-episode schizophrenia. Arch. Gen. Psychiatry 50 (1993), 369–376.
23. McIlwain, M.E., Harrison, J., Wheeler, A.J., Russell, B.R., Pharmacotherapy for treatment-resistant schizophrenia. Neuropsychiatr. Dis. Treat. 7 (2011), 135–149.
24. Meltzer, H.Y., Treatment-resistant schizophrenia–the role of clozapine. Curr. Med. Res. Opin. 14 (1997), 1–20.
25. Moncrieff, J., Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse. Acta Psychiatr. Scand. 114 (2006), 3–13.
26. Robinson, D., Woerner, M.G., Alvir, J.M., Bilder, R., Goldman, R., Geisler, S., Koreen, A., Sheitman, B., Chakos, M., Mayerhoff, D., Lieberman, J.A., Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch. Gen. Psychiatry 56 (1999), 241–247.
27. Samaha, A.N., Seeman, P., Stewart, J., Rajabi, H., Kapur, S., Breakthrough dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J. Neurosci. 27 (2007), 2979–2986.
28. Samaha, A.N., Reckless, G.E., Seeman, P., Diwan, M., Nobrega, J.N., Kapur, S., Less is more: antipsychotic drug effects are greater with transient rather than continuous delivery. Biol. Psychiatry 64 (2008), 145–152.
29. Seeman, P., Lee, T., Chau-Wong, M., Wong, K., Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261 (1976), 717–719.
30. Snyder, S.H., Dopamine receptors, neuroleptics, and schizophrenia. Am. J. Psychiatry 138 (1981), 460–464.
31. Suzuki, T., Kanahara, N., Yamanaka, H., Takase, M., Kimura, H., Watanabe, H., Iyo, M., Dopamine supersensitivity psychosis as a pivotal factor in treatment-resistant schizophrenia. Psychiatry Res. 227 (2015), 278–282.
32. Szymanski, S.R., Cannon, T.D., Gallacher, F., Erwin, R.J., Gur, R.E., Course of treatment response in first-episode and chronic schizophrenia. Am. J. Psychiatry 153 (1996), 519–525.
33. T.S.S.R. Group, The scottish first episode schizophrenia study: VIII. five-year follow-up: clinical and psychosocial findings. the scottish schizophrenia research group. Br. J. Psychiatry 161 (1992), 496–500.
34. Tadokoro, S., Okamura, N., Sekine, Y., Kanahara, N., Hashimoto, K., Iyo, M., Chronic treatment with aripiprazole prevents development of dopamine supersensitivity and potentially supersensitivity psychosis. Schizophr. Bull. 38 (2012), 1012–1020.
35. Tateno, A., Arakawa, R., Okumura, M., Fukuta, H., Honjo, K., Ishihara, K., Nakamura, H., Kumita, S., Okubo, Y., Striatal and extrastriatal dopamine D2 receptor occupancy by a novel antipsychotic, blonanserin: a PET study with [11C]raclopride and [11C]FLB 457 in schizophrenia. J. Clin. Psychopharmacol. 33 (2013), 162–169.
36. Tenjin, T., Miyamoto, S., Ninomiya, Y., Kitajima, R., Ogino, S., Miyake, N., Yamaguchi, N., Profile of blonanserin for the treatment of schizophrenia. Neuropsychiatr. Dis. Treat. 9 (2013), 587–594.
37. Yamanaka, H., Kanahara, N., Suzuki, T., Takase, M., Moriyama, T., Watanabe, H., Hirata, T., Asano, M., Iyo, M., Impact of dopamine supersensitivity psychosis in treatment-resistant schizophrenia: an analysis of multi-factors predicting long-term prognosis. Schizophr. Res. 170 (2016), 252–258.